Division of AstraZeneca PLC
Latest From Novexel SA
The latest biopharma industry appointments include C-suite hires at Hikma, Ipsen, Sinclair PeptiDream, Targovax, Nicox, Moderna, Antabio and Perrigo; as well as a supervisory board appointment at Kiadis.
AstraZeneca has, after a long gestation, given birth to the antibiotic developer Entasis Therapeutics: in early July the biotech debuted with $40 million in funding from AZ alone, and a portfolio of the drugmaker’s early-stage antibiotic candidates. It emerges as the debate about incentivizing antibiotics R&D intensifies amid growing concerns about antibiotic-resistant bacteria.
Spinifex Pharmaceuticals, a company developing new drugs for the treatment of chronic pain, has made two new appointments to enhance its chemistry, manufacturing and controls (CMC) capabilities. Dr Peter Spargo has joined Spinifex as senior vice-president, CMC. Previously Dr Spargo acted as an industry consultant, including to Spinifex, and held the role of SVP CMC at Creabilis (Italy and UK) and at Novexel (France).
Despite voting for two of three proposed indications for gram-negative antibiotic ceftazidime/avibactam, many FDA committee members pressed for additional studies and analyses, offering hints for future antibiotic advisory panels as well as potential post-market requirements for Actavis.
- Therapeutic Areas
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- AstraZeneca PLC
- Senior Management
Iain Buchanan, CEO
Kenneth Coleman, PhD, CSO
Carole Sable, MD, CMO
Aram Mangasarian, VP, Bus. Dev.
- Contact Info
Phone: (33) 57 14 07 77
102, avenue Gaston Roussel
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.